D.V. Litvinchuk
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
D.V. Litvinchuk has a total of 6 co-authors. Here are the top co-authors by number of shared publications:
- D. E. Danilau
Belarusian State Medical University, Minsk
2 shared publications - Igor A. Karpov
Belarusian State Medical University
2 shared publications D. Litvinchuk
1 shared publicationI. Karpov
1 shared publication- Olga V. Krasko
The United Institute of Informatics Problems of the National Academy of Sciences of Belarus
1 shared publication Д. Е. Данилов
Белорусский государственный медицинский университет
1 shared publication
Latest Publications
- Open Access
- 20 October 2026
- Published by The Republican Scientific and Practical Center of Medical Technologies, Informatization, Management and Economics of Public Health
- Vol. 1 (9) , 24-34
Clinical characteristics and efficacy of vaccination on severity in hospitalized patients with COVID-19 during different pandemic periods
Objective. To characterize clinical severity of COVID-19 in hospitalized patients during pandemic periods and to assess the effect of vaccination on disease course. Materials and methods. Single-centre retrospective cohort study of 11,203 patients hospitalized with COVID-19 in 2020– 2023 (112,455 bed-days). Clinical severity was graded on a four-level respiratory failure scale: «none»; «oxygen mask/cannula»; «noninvasive ventilation» (NIV); «invasive mechanical ventilation» (IMV). Bayesian hierarchical ordinal regression was fitted with covariates: age, Elixhauser comorbidity index, vaccination, previous-day respiratory failure, pandemic day and disease days. Statistical analysis was performed with programming languages R 4.6.0 and Stan 2.38.0. Results. The 28-day cumulative risk of respiratory failure was up to 50 % in the first wave, up to 80 % in the period of Alpha variant predominance, > 90 % (unvaccinated) and ≤ 65 % (vaccinated) in the period of Delta variant predominance, and ≤ 25 % in the Omicron. During predominance of Delta variant, the probability of NIV/IMV reached 25–30 % in older unvaccinated patients with comorbidities compared to ≤ 4.5 % in vaccinated ones; during predominance of Omicron variants it was < 1 %, though up to 20 % still required oxygen. After standardization, vaccination was associated with a lower cumulative risk from September 2021 to March 2022, peaking in December 2021: -24.3 % (95 % CI (-17,6; -30,6)). Conclusion. Respiratory failure severity varied by pandemic period, and vaccination against SARS-CoV-2 had a protective effect in hospitalized patients.
- 20 October 2026
- Published by The Republican Scientific and Practical Center of Medical Technologies, Informatization, Management and Economics of Public Health
- Vol. 1 (9) , 24-34
Open AccessClinical characteristics and efficacy of vaccination on severity in hospitalized patients with COVID-19 during different pandemic periods
Objective. To characterize clinical severity of COVID-19 in hospitalized patients during pandemic periods and to assess the effect of vaccination on disease course. Materials and methods. Single-centre retrospective cohort study of 11,203 patients hospitalized with COVID-19 in 2020– 2023 (112,455 bed-days). Clinical severity was graded on a four-level respiratory failure scale: «none»; «oxygen mask/cannula»; «noninvasive ventilation» (NIV); «invasive mechanical ventilation» (IMV). Bayesian hierarchical ordinal regression was fitted with covariates: age, Elixhauser comorbidity index, vaccination, previous-day respiratory failure, pandemic day and disease days. Statistical analysis was performed with programming languages R 4.6.0 and Stan 2.38.0. Results. The 28-day cumulative risk of respiratory failure was up to 50 % in the first wave, up to 80 % in the period of Alpha variant predominance, > 90 % (unvaccinated) and ≤ 65 % (vaccinated) in the period of Delta variant predominance, and ≤ 25 % in the Omicron. During predominance of Delta variant, the probability of NIV/IMV reached 25–30 % in older unvaccinated patients with comorbidities compared to ≤ 4.5 % in vaccinated ones; during predominance of Omicron variants it was < 1 %, though up to 20 % still required oxygen. After standardization, vaccination was associated with a lower cumulative risk from September 2021 to March 2022, peaking in December 2021: -24.3 % (95 % CI (-17,6; -30,6)). Conclusion. Respiratory failure severity varied by pandemic period, and vaccination against SARS-CoV-2 had a protective effect in hospitalized patients.
- 1 January 2026
- Published by Geotar-Media Publishing Group in Infectious diseases: News, Opinions, Training
- Vol. 15 (2)
Effect of tocilizumab on COVID-19 outcomes in hospitalized patients
- 1 January 2026
- Published by Geotar-Media Publishing Group in Infectious diseases: News, Opinions, Training
- Vol. 15 (2)
Effect of tocilizumab on COVID-19 outcomes in hospitalized patients